Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001569940 | SCV000653078 | benign | not provided | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000566851 | SCV000671473 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-08-24 | criteria provided, single submitter | clinical testing | The c.1687-3T>G intronic variant results from a T to G substitution 3 nucleotides upstream from coding exon 16 in the POLE gene. This nucleotide position is not well conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice acceptor site; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV001569940 | SCV001794114 | uncertain significance | not provided | 2022-11-23 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV005004231 | SCV005633756 | uncertain significance | Colorectal cancer, susceptibility to, 12; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome; Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency | 2024-04-11 | criteria provided, single submitter | clinical testing |